FIELD: medicine.
SUBSTANCE: invention touches upon treatment and diagnosis of lung cancer and metastases thereof. Proposed is a pharmaceutical composition to be used in a method for therapeutic or preventive treatment or for diagnosing ZP3 protein expressing lung cancer and/or metastases thereof in humans. The composition contains a source of an immunogenic polypeptide comprising at least one of the MHC Class I and II-restricted epitopes from the amino acid sequence of human zona pellucida protein 3 (hZP3), and at least one excipient. The source of the immunogenic polypeptide includes at least one immunogenic peptide comprising or consisting of amino acid sequence SEQ ID NO: 83, a nucleic acid molecule encoding the said immunogenic polypeptide and/or an immunogenic polypeptide expressing cell.
EFFECT: diagnosis and treatment of primary and/or recurrent ZP3 protein expressing lung cancer and metastases thereof.
11 cl, 7 dwg, 6 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| YEAST PRODUCING EKTOIN | 2018 |
|
RU2745157C1 |
| TNF RECEPTOR-BINDING AGONISTS | 2016 |
|
RU2821343C2 |
| ANTIBODIES TO SURFACE DETERMINANTS OF S. AUREUS | 2013 |
|
RU2808018C2 |
| ANTIBODIES TO S. AUREUS SURFACE DETERMINANTS | 2013 |
|
RU2698131C2 |
| EphA4 ANTIBODY | 2016 |
|
RU2719158C2 |
| INSECTICIDAL PROTEINS AND METHODS FOR USING THEM | 2016 |
|
RU2740312C2 |
| ANTIBODIES AGAINST OX40 AND THEIR USE | 2017 |
|
RU2783314C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| ANTI-LAG-3 ANTIBODIES | 2016 |
|
RU2760582C2 |
| IL-5 BINDING MOLECULE, METHOD OF ITS PREPARATION AND ITS USE | 2021 |
|
RU2811518C1 |
